TRACON Pharmaceuticals Inc (NAS:TCON)
$ 1.26 0.02 (1.63%) Market Cap: 3.38 Mil Enterprise Value: -4.95 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 27/100

TRACON Pharmaceuticals Inc Key Opinion Leader Webinar On Envafolimab For The Treatment Of Sarcoma Call Transcript

Jul 17, 2020 / 03:00PM GMT
Release Date Price: $38.4 (-4.95%)
Sara Parigian;LifeSci Advisors
LLC,

Good morning, and welcome to the TRACON KOL call on envafolimab for the treatment of sarcoma cancers. (Operator Instructions) As a reminder, this conference is being recorded, and a replay will be made available on the TRACON website following the event.

I would now like to turn the call over to your host, Brian Ritchie of LifeSci Advisors. Please go ahead, Brian.

Brian Ritchie
LifeSci Advisors, LLC - MD

Thank you, Sara, and thank you all for joining us this morning. Once again, welcome to TRACON Pharmaceuticals KOL webinar to discuss envafolimab for the treatment of sarcoma cancers.

Turning to Slide 2. Please note that certain information discussed on the webinar today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, TRACON management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to the risks and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot